Skip to search formSkip to main contentSkip to account menu

Oxi 4503

Known as: OXi4503, Oxi-4503 
National Institutes of Health

Related topics

Related topics

3 relations
CA1P

Broader (2)

DiphosphatesStilbenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)
Background AML depends on blood vessel networks for disease progression and protection from chemotherapy. In prior preclinical… 
Review
2011
Review
2011
Antiangiogenic therapies in epithelial ovarian cancer.
BACKGROUND Angiogenesis is a critical component of tumor development and proliferation, and increased angiogenesis has been… 
2010
2010
In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503.
4T1 mouse mammary adenocarcinomas and Caki-1 human renal cell carcinomas grown in mouse dorsal window chambers were serially… 
2010
2010
Ovariectomy causes immunosenescence and oxi-inflamm-ageing in peritoneal leukocytes of aged female mice similar to that in aged males
Immunosenescence involves age-associated restructuring changes of innate and adaptative immune functions. We have suggested that… 
Review
2008
Review
2008
Management of cutaneous hemangiomas in pediatric patients.
Cutaneous hemangiomas (CHs) are common benign vascular tumors of childhood. Clinically, they are characterized by a typical… 
2008
2008
Alterations in vascular architecture and permeability following OXi4503 treatment
OXi4503 retards tumor growth in a dose-dependent manner and improves survival in a murine model of colorectal liver metastases… 
2008
2008
Phase I evaluation of vascular disrupting agent OXi4503
3551 Background: OXi4503 is the pro-drug of OXi4500 (Combretastatin A1), a tubulin binding vascular disrupting agent that also… 
Review
2007
Review
2007
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Vascular disrupting agents (VDAs) are a new class of potential anticancer drugs that selectively destroy tumor vasculature and… 
2007
2007
Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis.
BACKGROUND Oxi4503 has been shown to inhibit tumor growth and improve survival in an animal model of colorectal (CRC) liver… 
2006
2006
Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)